Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,741 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemorrhage Clear all
Completed No phase listed Observational

Effectiveness of the Adding High Fidelity Simulation to the Bleeding Control Course in Regards to Proper Tourniquet Placement Amongst School Personnel

NCT04293211
View directory record Official record
Conditions
Tourniquet Placement, Wound Packing
Interventions
Simulation
Other
Lead sponsor
White Plains Hospital
Other
Eligibility
18 Years and older
Enrollment
66 participants
Timeline
2019
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 19, 2026, 7:20 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

NCT01047722
View directory record Official record
Conditions
Healthy
Interventions
Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.
Drug · Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Newport Beach, California • San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Early Phase 1 Interventional Results available

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

NCT04088630
View directory record Official record
Conditions
Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
Interventions
Fingolimod, Placebo, Open-label Fingolimod
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 19, 2026, 7:20 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 7:20 AM EDT
Recruiting Phase 3 Interventional

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
View directory record Official record
Conditions
Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Shirley, New York • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury

NCT03496545
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage
Interventions
Bromocriptine 5 MG, Acetaminophen 650 MG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT01098487
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag olamine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Role of Topical Tranexamic Acid in Total Hip Arthroplasty

NCT01866943
View directory record Official record
Conditions
Post Operative Blood Loss
Interventions
Tranexamic Acid, Normal Saline Solution
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

NCT03037515
View directory record Official record
Conditions
Blood Loss, Surgical, Blood Loss Anemia
Interventions
Tranexamic Acid
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding

NCT02640235
View directory record Official record
Conditions
Bleeding Active
Interventions
CELSTAT, Surgicel Original
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 19, 2026, 7:20 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities

NCT03996317
View directory record Official record
Conditions
Perinatal Death, Respiratory Distress Syndrome, Newborn, Hypoxic-Ischemic Encephalopathy, Neonatal Seizure, Meconium Aspiration Syndrome, Intracranial Hemorrhages, Neonatal Hypotension
Interventions
Room air
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 19, 2026, 7:20 AM EDT
Recruiting Phase 3 Interventional

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 1 Interventional

Vascular Sealant Study

NCT00618358
View directory record Official record
Conditions
Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts
Interventions
Vascular Sealant System, Gelfoam/Thrombin
Device · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Timeline
Started 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)

NCT02039297
View directory record Official record
Conditions
Critical Illness, Sepsis, Respiratory Failure, Shock, Coma, Bleeding, Trauma
Interventions
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Lawrence, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

NCT01932060
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Oxytocin Infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

NCT00799773
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04224688
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
St. Petersburg, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Not listed Early Phase 1 Interventional

Inhalational Anesthesia vs TIVA in Endoscopic Tympanoplasty

NCT05993039
View directory record Official record
Conditions
Perforated Eardrum
Interventions
Isoflurane Inhalant Product, Sevoflurane inhalant product, Propofol injection, Remifentanil Injection
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
0 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional

Examining the Effect of Ondansetron on Bowel Prep Success

NCT05439772
View directory record Official record
Conditions
Abdominal Pain, Inflammatory Bowel Diseases, Eosinophilic Gastroenteritis, Diarrhea, Hematochezia, Weight Loss
Interventions
Ondansetron
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
2 Years to 20 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients

NCT05973747
View directory record Official record
Conditions
Postpartum Hemorrhage, Pregnancy Related, Hypocalcemia, Parturition Complication
Interventions
Calcium Gluconate, Calcium chloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

NCT02353247
View directory record Official record
Conditions
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Interventions
Norethindrone acetate
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases

NCT01469585
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
Doxycycline
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Anticoagulation With Enhanced Gastrointestinal Safety

NCT05563714
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
Interventions
Clinician Notification with Nurse Facilitation (CNNF), Wait list control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 19, 2026, 7:20 AM EDT